Imunon (IMNN) vs Scienture (SCNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scienture is the larger company by market cap ($6.2 million vs $6.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNN | SCNX |
|---|---|---|
| Share price | $1.08 | $3.76 |
| Market cap | $6.06M | $6.18M |
| 1-day change | +0.93% | -2.59% |
| EPS (TTM) | $-3.84 | $-52.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.39 | $65.00 |
| 52-week low | $0.96 | $3.23 |
| Distance from 52-week high | -79.96% | -94.22% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +1474.07% | +897.34% |
| Average volume | 155.30K | 212.16K |
| Shares outstanding | 5.61M | 1.64M |
| Employees | 20 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Imunon
IMNN stock →Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Scienture
SCNX stock →Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
IMNN vs SCNX FAQ
Which is bigger, Imunon or Scienture?
Scienture (SCNX) is larger, with a market capitalization of $6.18M compared with $6.06M for Imunon (IMNN).
Are Imunon and Scienture in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.